R

Arcus Biosciences

D
RCUS
USD
1.387
(8.4214%)
Market Closed
34,925.00
Volume
-2.28
EPS
-
Div Yield
-5.749196
P/E
1,632,620,956.79
Market Cap
Today
8.4214%
1 Week
15.206%
1 Month
2.274%
6 Months
17.172%
12 Months
11.606%
Year To Date
-6.410%
All Time
0%

Title:
Arcus Biosciences

Sector:
Healthcare
Industry:
Biotechnology
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Do you need help or have a question?